Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 591 clinical trials
Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

positive cohort). The subjects from the run in safety part will be included in the Phase II analysis. Tumor expression of programmed cell death ligand 1 (PD-L1) is not required for enrollment in the study

breast adenocarcinoma
stage iv breast cancer
triple negative breast cancer
epidermal growth factor receptor
paclitaxel
  • 2 views
  • 26 Jan, 2021
  • 1 location
Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy

Immune checkpoint inhibitors (monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD- L1

  • 0 views
  • 26 Jan, 2021
  • 1 location
The Efficacy of Immunodetection Point Inhibitors for Advanced Esophageal Cancer

immunotherapy, immunocheckpoint inhibitors, including pd-1 inhibitors, pd-l1 inhibitors and ctla-4 inhibitors, have achieved significant curative effect and made breakthroughs in the treatment of multiple

  • 0 views
  • 23 Jan, 2021
  • 1 location
Radiogenomics in Aerodigestive Tract Cancers

results showed that the level of PD-L1 expression is associated with radiomics as well. The investigators plan to add genomic data into radiomics and interrogate cancers from different aspects. The

  • 0 views
  • 27 Jan, 2021
  • 1 location
Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.

cancer chemotherapy
non-squamous non-small cell lung cancer
lung carcinoma
squamous non-small cell lung cancer
  • 0 views
  • 24 Jan, 2021
  • 1 location
CT-based Radiomic Algorithm for Assisting Surgery Decision and Predicting Immunotherapy Response of NSCLC

The purpose of this study was to investigate whether the combined radiomic model based on radiomic features extracted from focus and perifocal area (5mm) can effectively improve prediction performance of distinguishing precancerous lesions from early-stage lung adenocarcinoma, which could assist clinical decision making for surgery indication. Besides, response and long …

ct scan chest
adenocarcinoma
lung carcinoma
ct scan
lung cancer
  • 0 views
  • 24 Jan, 2021
  • 2 locations
Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIIA

This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in stage IIIA NSCLC patients.Interventional study

kidney function test
kinase inhibitor
neutrophil count
targeted therapy
lung carcinoma
  • 2 views
  • 24 Jan, 2021
  • 1 location
Chromosomal Instability as a Surrogate Biomarker of Drug Resistance in Immunotherapy for Lung Cancer Patients

PD1, as an immune checkpoint inhibitor, has provided a new therapeutic approach for patients with cancer, including patients. Although immunotherapy has proven effective, most patients do not benefit from it because of a large proportion which developing primary and acquired resistance. However, there is still a lack of accurate and …

lung carcinoma
ROS1
lung cancer
antineoplastic
cancer
  • 0 views
  • 23 Jan, 2021
  • 1 location
Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response

Immunotherapy with agents stimulating the immune system to act against cancer are now a new standard of care in various cancers as lung cancer and melanoma, but also bladder cancer, kidney cancer and head & neck cancer. However, even though a subset of patients derives long-term benefit from these agents, …

stage iv non-small cell lung cancer
docetaxel
nivolumab
bladder cancer
cancer
  • 1 views
  • 24 Jan, 2021
LIFE - Lung Cancer Immunotherapy Frailty Effect

The LIFE study (Lung cancer, Immunotherapy, Frailty, Effect) is investigating the unselected 'real life' non-small cell lung cancer (NSCLC) population treated with immune checkpoint inhibition.

  • 0 views
  • 27 Jan, 2021
  • 1 location